IMSA101 not checked
ImmuneSensor Therapeutics Inc.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Intra-tumoral administration on Days 1 and 15 of every 28-day cycle”In the company’s words, NCT06026254 on ClinicalTrials.gov
- Tested for
- Solid Tumor, Adult
- Main trialPhase 1
- “This is a rollover study from parent protocol IMSA101-101 for adult patients with advanced malignancies that were previously receiving IMSA101 and who would continue to receive benefit with study treatment of IMSA101 in combination with an immune checkpoint inhibitor (ICI).”In the company’s words, NCT06026254 on ClinicalTrials.gov
Other drugs for Solid Tumor, Adult
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | Sep 2025 | A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial | |
| Phase 2Terminated | 16 Sep 2024 | Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC | |
| Phase 2Terminated | 20 Nov 2024 | Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies | |
| Phase 1/2Completed | 15 Sep 2023 | Safety and Efficacy Study of IMSA101 in Refractory Malignancies |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026